Core Viewpoint - Tonghua Pharmaceutical has recently been granted three invention patents by the National Intellectual Property Administration, which are expected to enhance the company's competitive edge in the pharmaceutical industry [2] Group 1 - The company received three invention patent certificates with patent numbers ZL202311220522.8, ZL202411365642.1, and ZL202410014759.9 [2] - The announcement date for the patent grants was February 6, 2026, and the patents have a validity period of 20 years [2]

Core Viewpoint - The company, Aoxiang Pharmaceutical, has received a new High-tech Enterprise Certificate, indicating its recognition as a high-tech enterprise by relevant authorities in Zhejiang Province, which is crucial for its ongoing operations and potential funding opportunities [1] Group 1 - Aoxiang Pharmaceutical announced the receipt of the High-tech Enterprise Certificate from the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1] - The certificate was issued on December 19, 2025, and is valid for three years [1] - This recognition is a renewal of the company's previous certificate, which had expired [1]

Core Viewpoint - The company has approved a proposal to use up to 180 million yuan of temporarily idle raised funds for cash management, focusing on low-risk, high-security investment products [1] Group 1: Proposal Details - The board meeting will be held on February 9, 2026, to review the proposal for cash management [1] - The approved amount for cash management is not to exceed 180 million yuan, which includes over-raised funds [1] - The investment products will include structured deposits, time deposits, financial institution income certificates, notice deposits, and large-denomination certificates of deposit [1] Group 2: Investment Strategy - The selected investment products are characterized by high safety, good liquidity, and low risk [1] - The effective period for the cash management strategy is 12 months from the date of approval by the first extraordinary general meeting of shareholders in 2026 [1] - The funds can be rolled over within the approved limit without affecting the progress of the raised funds investment projects and the company's normal production and operations [1]

Group 1 - Company Tonghe Pharmaceutical recently announced the receipt of three invention patent certificates from the National Intellectual Property Administration of China [1] - The patents include methods for the preparation of key intermediates for Resmetirom, as well as methods and applications for pyrazine compounds and their nitro derivatives, and the preparation method for Upatacitinib intermediates [1]

Group 1 - The core point of the article is that Tonghua Golden Horse has completed the comprehensive review of its new chemical drug, Amber Tetrahydroaminoacridine Tablets, and is now in the final review stage [2] - The company has provided all required professional research materials as part of the review process [2] - The company will disclose any significant information regarding the new drug through designated information disclosure media, urging investors to pay attention to company announcements [2]

Core Viewpoint - Rundu Co., Ltd. has received the drug registration certificate for Candesartan Cilexetil Tablets from the National Medical Products Administration, indicating the product's approval for the treatment of primary hypertension [1] Company Summary - Rundu Co., Ltd. is now authorized to market Candesartan Cilexetil Tablets, which are specifically indicated for primary hypertension [1]

Group 1 - The core viewpoint of the news is that Borui Pharmaceutical is expected to experience a significant decline in net profit for the year 2025, with projections indicating a decrease of 67.28% to 78.17% compared to the previous year [1] - The forecasted net profit attributable to the parent company for 2025 is estimated to be between 41.3 million yuan and 61.9 million yuan, while the net profit after deducting non-recurring gains and losses is expected to range from 430,000 yuan to 2.49 million yuan, reflecting a year-on-year decrease of 86.21% to 97.62% [1] - The decline in performance is attributed to several factors, including changes in flu trends, shifts in competitive landscape, fluctuations in customer demand, reduced operating revenue and gross profit, increased depreciation from completed construction projects, and higher R&D expenses due to increased investment in innovative drugs [1] Group 2 - Dongfang Jincheng International Credit Rating Co., Ltd. has maintained the credit rating of Borui Pharmaceutical and its convertible bonds at AA- with a stable outlook, following a regular tracking rating on May 27, 2025 [2] - The rating results are effective from the date of the report and will remain valid throughout the duration of the rated debt [2] - Dongfang Jincheng will continue to monitor the developments related to Borui Pharmaceutical's operational and financial status and disclose any impacts on the credit rating and outlook for both the company and its convertible bonds [2]

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit attributable to shareholders decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Haiprui is 18.062 billion yuan, with a trading volume of 52.6162 million yuan on February 9 [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan in the last three years [8]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited is the eighth largest circulating shareholder, holding 12.0093 million shares, an increase of 691,700 shares from the previous period [9].

Core Insights - The main market saw a net inflow of 26.126 billion yuan as of February 9, indicating a positive trend in overall market sentiment [1]. Sector Analysis - The top ten sectors with the largest net outflows of funds were as follows: - **Beverage Industry**: Experienced a net outflow of 1.523 billion yuan, with Huangtai Liquor being the largest contributor to this outflow [2]. - **Precious Metals**: Saw a net outflow of 1.278 billion yuan, primarily driven by Shandong Gold [2]. - **General Equipment**: Had a net outflow of 0.985 billion yuan, with Yingliu Co. being the main affected company [2]. - **Chemical Pharmaceuticals**: Experienced a net outflow of 0.693 billion yuan, with Xinhengcheng as the largest contributor [2]. - **Traditional Chinese Medicine**: Faced a net outflow of 0.635 billion yuan, with Guangdong Wannianqing leading the outflow [2]. - **Biological Products**: Saw a net outflow of 0.540 billion yuan, with Wanze Co. being the most impacted [2]. - **Oil Industry**: Experienced a net outflow of 0.483 billion yuan, with Heshun Oil being the largest contributor [3]. - **Agriculture, Animal Husbandry, and Fishery**: Had a net outflow of 0.422 billion yuan, with Xue Rong Biological being the main affected company [3]. - **Commercial Retail**: Faced a net outflow of 0.418 billion yuan, with Wangfujing leading the outflow [3]. - **Telecommunication Services**: Experienced a net outflow of 0.375 billion yuan, with Erli San being the largest contributor [3].

Core Insights - Longhua Technology (联化科技) is positioned as a leading player in the agricultural and pharmaceutical CDMO sectors, with significant achievements in small nucleic acid CDMO and potential in functional chemicals [1][2] Business Overview - Longhua Technology has established a collaborative development framework across four core industrial segments: agricultural protection, pharmaceuticals, functional chemicals, and equipment & engineering services [2] - The agricultural protection segment generated revenue of 1.702 billion yuan in the first half of 2025, with a gross margin increase of 9.48% year-on-year [2] - The pharmaceutical segment, focusing on APIs and intermediates, achieved revenue of 1.018 billion yuan in the first half of 2025, reflecting a year-on-year growth of 42.80% [2] Small Nucleic Acid CDMO - The company is leveraging small nucleic acid CDMO to tap into new growth opportunities, with advantages over traditional small molecule and antibody drugs, including broader target selection and higher success rates [3] - Since 2022, the market for small nucleic acid drugs has seen significant activity, with 32 transactions totaling 29.022 billion USD in 2025, indicating strong commercial value [3] - Longhua Technology has developed scalable production processes for modified nucleotides and has established a high-efficiency delivery system for nucleic acid drugs, enhancing its competitive edge [3] Functional Chemicals and Market Potential - The functional chemicals segment reported revenue of 0.265 billion yuan in the first half of 2025, marking a year-on-year doubling [4] - The company is focusing on lithium battery materials, including lithium hexafluorophosphate and LiFSI, with ongoing product development in various testing phases [4] - The National Development and Reform Commission's new storage action plan aims for over 1.8 million kilowatts by 2027, which is expected to drive significant market demand in the energy storage sector [4] Financial Performance - For the first three quarters of 2025, Longhua Technology reported total revenue of 4.718 billion yuan, an increase of 8.25% year-on-year, and a net profit of 316 million yuan, surging by 871.65% [1] - The projected net profit for 2025 is estimated to be between 350 million and 420 million yuan, representing a year-on-year growth of 239.35% to 307.22% [4]